🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Great piece here by Stephen John Senn. The only question I have really is how can we make optimal decisions when powering Frequentist trials for a fixed delta, because what patients care about P(effect > e | data) is not fixed e, curious to Frank Harrell thoughts errorstatistics.com/2025/05/16/reb…

Way to go SOUMYAJIT ROY and Michael Ong!

Keys to maximizing academic productivity as a trainee

Shilpa Gupta The Lancet Oncology Matt Galsky Sumanta K. Pal, MD, FASCO Cristiane D Bergerot Petros Grivas Michiel van der Heijden Umang Swami Toni Choueiri, MD Jame Abraham, MD, FACP Ashish M. Kamat, MD, MBBS Congrats Shilpa Gupta on your oral presentation of the EV-302 HRQOL data in ASCO #ASCO25 and simultaneous publication in The Lancet Oncology Tom Powles Umang Swami

🗣️Prostate Rapid Oral Abstract #ASCO25 👉Abt5013: Dr Praful Ravi presenting Docetaxel + ADT + XRTR for high risk localized PC (HRLPC) using individual patient data from #ICECAP n = 1690 from 4RCTs High-risk: 1 RF (Gleason ≥8, PSA >20, ≥cT3) Very high-risk: 2-3

Another great ICECAP study showing in large 4 study IPD meta, addition of Doce to RT+ADT did not significantly improve OS. meetings.asco.org/abstracts-pres… Aligns with current National Comprehensive Cancer Network (NCCN) to not recommend Doce using current risk stratification methods for non-M1 disease. Most high risk dz

Despite RP + RT patients generally younger/healthier than RT patients (and very outdated RT), this observational non-randomized study shows RP+RT have highest risk of urinary adverse events. Important counseling for high risk PCa given trials consistently demonstrate ~80% will

Just in from ASCO #ASCO25 👉📢 Finally a T-cell engager in #prostatecancer mCRPC with minimal CRS syndrome (only grade 1, all outpatient dosing) and promising efficacy👇 Congrats #drbaldini Mark Stein and team Journal of Clinical Oncology OncoAlert UroToday.com PCF Science

Wonderful presentation by Chadi Hage Chehade at #ASCO2025

👉🏻 Superstar Zeynep Irem Ozay, MD presenting ASCO our real-world data showing lutetium has better survival outcomes than cabazitaxel in post-ARPI/docetaxel mCRPC patients. #ASCO25 ASCO #ProstateCancer GU Cancer Research Program @HuntsmanCancer Neeraj Agarwal, MD, FASCO OncoAlert UroToday.com

Our own Angela Jia presenting her excellent insights into prostate cancer abstracts #ASCO25 University Hospitals Case Comp Cancer Ctr

So poised discussion by Dr. Jia Angela Jia

nice job by Michael Ong promoting the need to support TRIPLE-SWTICH… let’s see if acting on this PSA threshold is important. #ASCO25

#ASCO25 | Dr. Ong on PSA kinetics in mHSPC (IRONMAN registry): 🧬 Real-world ADT+ARPI-treated pts (n≈4,586) 📊 PSA at 6–12 mo is prognostic  • PSA ≥0.2 = poor OS/PFS  • PSA <0.1 = best outcomes 📉 PSA level stratified survival regardless of doublet vs triplet tx 📌 Supports

Congrats Michael Ong for the stellar talk ASCO #ASCO25 👉 PSA response (<0.2 ng/ml) after starting ADT+ARPI in mHSPC #prostatecancer (occurred in 50% of pts) associated with ⬆️OS (& 5-fold ⬆️ in death if PSA is >\=0.2). OncoAlert UroToday.com PCF Science Dan George

As shown by Michael Ong ASCO #asco25 👉 treatment escalation (SWOG Cancer Research Network Triple Switch/CCTG, and de-escalation trials have been started based on PSA response in mHSPC #prostatecancer OncoAlert UroToday.com PCF Science

Two slides from #ASCO2025 prostate oral session today. What's wrong with them? I will leave the further discussion to folks who are constantly teaching me M. Bolton Pavlos Msaouel Yilun Sun Amit Chowdhry, MD, PhD

That’s my bestie/partner-in-crime! Way to go Angela Jia 🥳 Killing it as usual.

sciencedirect.com/science/articl…

Cross-Comparison Individual Patient-Level Analysis of Three Gene Expression Signatures in Localized Prostate in Over 50,000 Men | JCO Precision Oncology ascopubs.org/doi/10.1200/PO… nice work RadOncUH Angela Jia